anthrax vaccine adsorbed + raxibacumab

**Anthrax vaccine adsorbed + raxibacumab** is a combination therapy intended for post-exposure prophylaxis or treatment of inhalational anthrax caused by *Bacillus anthracis*. **Anthrax vaccine adsorbed (AVA)** is a vaccine composed primarily of adsorbed protective antigen, designed to stimulate an immune response and induce protective antibodies. **Raxibacumab** is a recombinant human monoclonal antibody that binds to the protective antigen part of the anthrax toxin, preventing its attachment to host cell receptors and thereby neutralizing the effects of the toxin. When co-administered, raxibacumab provides immediate passive immunity while AVA confers active, long-term immunogenicity; clinical research has shown no negative impact on vaccine immunogenicity from the combination, and animal and human data indicate potential added benefit for both treatment and post-exposure prophylaxis[1][3][4][5].